Matthew Hellmann

46PUBLICATIONS
386CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Apr 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.

Federica Pecci, Rohit Thummalapalli, Stephanie L Alden

|Nov 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.

Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi

|Jul 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.

Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar

|Dec 21, 2023
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.

Miguel Lopez de Rodas, Yvonne Wang, Gang Peng

|Dec 18, 2023
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.

Arielle Elkrief, Nicholas R Waters, Natalie Smith

|Jul 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.

Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti

Pageof 8

Frequent Collaborators

11 joint publications

Charles M Rudin

7 joint publications

Adam J Schoenfeld

7 joint publications

Jamie E Chaft

7 joint publications

Andrew Plodkowski